Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

166.17 -2.83 (-1.67%)
Streaming Delayed Price Updated: 3:23 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade
 
Via Benzinga
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
 
Via Benzinga
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline
 
Via Benzinga
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
 
Via Benzinga
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
 
Via Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
 
Via Benzinga
AstraZeneca's Imfinzi Combo Scores FDA Approval For Liver Cancer
 
Via Benzinga
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
 
Via Benzinga
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
 
Via Benzinga
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
 
Via Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
 
Via Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
 
Via Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
 
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
 
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
 
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
 
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
 
Via Benzinga
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
 
Via Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
 
Via Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
 
Via Benzinga
European Regulator Grants Complete Approval To AstraZeneca's COVID-19 Vaccine
 
Via Benzinga
AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
 
Via Benzinga
AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings
 
Via Benzinga
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
 
Via Benzinga
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
 
Via Benzinga
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection. 
Via Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
 
Via Benzinga
How To Invest In UK Market Turmoil
With investors speculating about what steps the central bank might take, it’s clear that the UK’s turbulence is far from over. So, let’s take a look at the market winners and losers that are likely to... 
Via Talk Markets
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
 
Via Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.